Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512725 | 0.86 | CYP3A4 (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL512267 | 0.85 | LMNA (0.38) | HTR2AHTR2CHTR2BMAT2ALMNA | |
| SCHEMBL512159 | 0.84 | SLC6A2 (0.32) | SLC6A2SLC6A3SLC6A4HTR2AHTR2C | |
| SCHEMBL512355 | 0.81 | CYP3A4 (0.38) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12685562 | 0.81 | KDM4E (0.32) | SLC6A2SLC6A3SLC6A4HTR2B | |
| SCHEMBL10258090 | 0.80 | HRH4 (0.36) | HTR2CHTR2BL3MBTL1 | |
| SCHEMBL512227 | 0.80 | HRH4 (0.36) | HTR2CHTR2BL3MBTL1 | |
| SCHEMBL512499 | 0.80 | HRH3 (0.36) | MCHR1HTR2AHTR2CHTR2BLMNA | |
| SCHEMBL16330063 | 0.77 | CRBN (0.32) | — | |
| SCHEMBL512383 | 0.77 | TUBB4A (0.40) | SLC6A3SLC6A4HTR2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SLC6A2 2119/4885SLC6A3 3345/4885SLC6A4 3218/4885 |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SLC6A2 2119/4885SLC6A3 3345/4885SLC6A4 3218/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SLC6A2 2119/4885SLC6A3 3345/4885SLC6A4 3218/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SLC6A2 2119/4885SLC6A3 3345/4885SLC6A4 3218/4885 |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SLC6A2 2119/4885SLC6A3 3345/4885SLC6A4 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.